Oxford Biomedica plc (OXB.L)

315,00 -5,00 (-1,56%) Börsenschluss: 04:35PM BST

Oxford Biomedica plc

Windrush Court
Transport Way
Oxford OX4 6LT
United Kingdom
44 1865 783 000
https://www.oxb.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 714

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Stuart Paynter	CFO & Director	832k	N/A	1972
Dr. Frank Mathias	CEO & Director	N/A	N/A	1962
Mr. Thierry Cournez	COO & Oxford Site Head	N/A	N/A	N/A
Dr. James Miskin Ph.D.	Chief Quality & Technical Officer	N/A	N/A	N/A
Mr. Matthew Treagus	Chief Information Officer	N/A	N/A	N/A
Sophia Bolhassan	Head of Investor Relations	N/A	N/A	N/A
Ms. Natalie Louise Walter	General Counsel & Company Secretary	N/A	N/A	1973
Ms. Lisa James	Chief People Officer	N/A	N/A	N/A
Dr. Kyriacos Mitrophanous Ph.D.	Chief Innovation Officer	N/A	N/A	N/A
Ms. Kati Hudson	Head of Intellectual Property and Contracts	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in GBp.

Beschreibung

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Corporate Governance

Oxford Biomedica plcs ISS Governance QualityScore, Stand 1. Mai 2024, lautet 9. Die grundlegenden Scores sind Audit: 8, Vorstand: 6, Shareholderrechte: 1, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.